The Study Everyone in the Functional Medicine Space Is Talking About

A 12-week observational study published in Life (MDPI) in late 2025 and circulating widely in 2026 evaluated what happens when supplementation is tailored to an individual’s baseline biomarker profile rather than prescribed generically.

The protocol enrolled 48 participants (8 per age/sex group, ages 40–69) and built personalised supplement protocols based on individual lab panels. The interventions included vitamin D, omega-3 fatty acids, B vitamins, zinc, selenium, and — in some participants — hormone optimisation support.

The headline numbers: CRP decreased 33–46% across all groups. Homocysteine dropped 29–37%. WBC counts fell 22–28%. In older male participants, ferritin reductions reached 48%. Women showed the most pronounced declines in anti-TPO antibodies (thyroid peroxidase antibodies, a marker of Hashimoto’s activity) — up to 22%.

These are genuinely interesting numbers. Let me explain why — and also why you should read them critically.

What “Biomarker-Guided” Actually Means Here

The personalisation in this study was relatively straightforward: participants were started on supplements that addressed documented deficiencies or insufficiencies identified on their baseline labs. If your 25-OH vitamin D was 22 ng/mL, you got vitamin D. If your omega-3 index was low, you got fish oil. If your homocysteine was elevated and B12/folate borderline, you got methylated B vitamins.

This is not pharmacogenomics. This is not genome-guided prescribing. This is correcting measurable nutritional deficiencies — which, frankly, works. We have decades of data showing that correcting vitamin D deficiency reduces inflammatory markers, that omega-3 supplementation in deficient states reduces CRP, that methylated folate in people with suboptimal homocysteine reduces cardiovascular risk markers.

The contribution of this study is less about a new discovery and more about quantifying what happens when you systematically correct multiple insufficiencies simultaneously, in age- and sex-stratified groups, with consistent measurement.

What’s Genuinely Notable

The anti-TPO finding matters. A 22% reduction in anti-TPO antibodies over 12 weeks is clinically meaningful for Hashimoto’s patients. Anti-TPO is a direct marker of thyroid autoimmune activity. The primary nutrients implicated here — selenium (200mcg/day as selenomethionine has the strongest evidence), vitamin D, and omega-3s — have individually shown anti-TPO-lowering effects in RCTs. Seeing the combination produce this magnitude of effect in a real-world population is useful confirmation.

The homocysteine reductions are expected but important. Elevated homocysteine is a cardiovascular risk factor and also correlates with B-vitamin insufficiency, particularly B12, B6, and folate. The 29–37% reductions here align well with the established literature on methylated B-vitamin supplementation in people with elevated baseline homocysteine. Critically, whether the participants had MTHFR variants is not reported — and MTHFR C677T homozygotes in particular benefit most from methylated rather than folic acid forms of folate. That’s a methodological gap.

The age and sex stratification adds value. Most supplement studies don’t look at differential responses by age group within the same trial. The finding that older males showed the largest ferritin reductions (48%) while women showed the most anti-TPO reduction suggests that response patterns are meaningfully heterogeneous — which supports the case for personalisation over generic protocols.

The Limitations You Need to Know

No control group. This is an observational study. There is no placebo arm. Regression to the mean — the statistical tendency for extreme values to move toward average on re-testing — can account for a substantial portion of the improvements seen. If you select participants with elevated CRP and retest them 12 weeks later, some improvement is expected regardless of intervention.

Short duration. Twelve weeks is long enough to see acute changes in inflammatory markers, but too short to know whether improvements are sustained, whether any benefit is durable after supplementation is reduced or stopped, or whether clinical outcomes (disease activity, hospitalisations, quality of life) are affected.

The protocol was comprehensive. Multiple supplements were started simultaneously. It is impossible to attribute the observed changes to any single intervention. The “personalised” framing obscures that most participants were effectively receiving a broad-spectrum micronutrient correction protocol.

The Practical Takeaway

Here’s what I’d actually extract from this study for clinical practice:

1. Test before you supplement. The reason this study worked is because people who needed vitamin D got vitamin D, not because they were prescribed it generically. Getting baseline labs (25-OH vitamin D, omega-3 index, B12, folate, homocysteine, ferritin, CRP, TSH + anti-TPO if autoimmune thyroid disease is a concern) gives you a rational foundation.

2. Selenium for Hashimoto’s is underused. The anti-TPO data here joins a meaningful body of RCT evidence. 200mcg/day of selenomethionine for 3–6 months in Hashimoto’s patients with elevated anti-TPO is worth discussing with your physician.

3. The MTHFR gap in this study is significant. If you have elevated homocysteine and you’re not responding to standard B-vitamin supplementation, MTHFR genotyping is warranted. The difference between folic acid (which cannot be processed by MTHFR C677T homozygotes efficiently) and methylfolate (5-MTHF) is clinically real.

4. Personalisation matters, but the bar isn’t genetic profiling — it’s basic labs. Most of the benefit in this study came from fixing things that a standard lab panel can identify. That’s achievable today, through any GP or functional medicine practitioner.

Sources: Personalized Supplementation Is Associated with Reduced Inflammatory Biomarkers: A 12-Week Observational Study. Life (MDPI) 2025, NCBI/PMC 2026; Biomarker-Guided Dietary Supplementation: A Narrative Review. Nutrients (MDPI) 2024.